Document Detail

Immunomodulation in vitro. The predictive value of in vitro testing of lung cancer patients' lymphocyte responsiveness to stimulation by Thymex L. A preliminary report.
MedLine Citation:
PMID:  9387906     Owner:  NLM     Status:  MEDLINE    
Eleven lung cancer patients were selected for combined radio and immunotherapy with a thymic agent-Thymex L. The selection criteria included the pre-therapy testing of patients' immunocompetence and the responsiveness of their lymphocytes to the in vitro addition of Thymex L: only patients with a significant degree of immunodepression, whose depressed cellular immunity parameters (the number of total and active T cells and their mitogen-induced lymphoproliferative response) were significantly increased upon this agent's action in vitro, entered the study. The results of the pre-therapy in vitro stimulation correlated with those obtained after completion of radioimmunotherapy: the administration of Thymex L along with radiotherapy seances prevented iatrogenic deterioration of initial depression of general immunocompetence and enabled to overcome it to a certain degree. This indicates that pre-therapy in vitro testing has a true predictive value. However, the initial immune disturbances were not normalized by immunotherapy; the post-therapy testing of the patients' lymphocytes to the addition of Thymex L in vitro showed that these cells possessed a residual potential to respond by a significant increase of the active T cell number and proliferative capacity, suggesting that immunotherapy could be prolonged in order to potentiate cellular immunity in immunodepressed lung cancer patients.
L Vucković-Dekić; N Stanojević-Bakić; L Rajner; M Dekić; M Pesić
Related Documents :
23062036 - The discovery and development of selective estrogen receptor modulators (serms) for cli...
6602096 - Types of immune complexes in the ascitic fluid of women with carcinoma of the ovary.
24524686 - Breathlessness and crises in the context of advanced illness: a comparison between copd...
22918696 - Surgery for relapsed ovarian cancer: when should it be offered?
24643996 - Designing fractal nanostructured biointerfaces for biomedical applications.
16616326 - Considering the potential benefits as well as adverse effects of sun exposure: can all ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of experimental & clinical cancer research : CR     Volume:  16     ISSN:  0392-9078     ISO Abbreviation:  J. Exp. Clin. Cancer Res.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1998-01-27     Completed Date:  1998-01-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8308647     Medline TA:  J Exp Clin Cancer Res     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  309-12     Citation Subset:  IM    
Institute for Oncology and Radiology of Serbia, Beograd, Yugoslavia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use*
Combined Modality Therapy
Immunologic Tests
Lung Neoplasms / immunology*,  radiotherapy,  therapy*
Lymphocyte Activation / drug effects*,  immunology*
Phytohemagglutinins / pharmacology
Predictive Value of Tests
Stimulation, Chemical
T-Lymphocytes / drug effects*,  immunology*
Thymus Extracts / therapeutic use*
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Phytohemagglutinins; 0/Thymus Extracts; 104841-70-5/Thymex-L

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  fMLP-induced CD11b/CD18 upregulation on neutrophils from patients with non-Hodgkin's lymphomas treat...
Next Document:  Medium-large polyps of the colon: a contribution for their clinical profile and a proper surveillanc...